carotuximab

Drug Overview

Carotuximab is an innovative medicine currently being studied to treat different types of cancer. It is known as a Targeted Therapy and an Immunotherapy. Instead of attacking all the cells in the body like traditional chemotherapy, it specifically targets the blood vessels that feed the cancer, cutting off its nutrient supply.

• Generic Name: Carotuximab (also known in research as TRC105 or ENV105)
• US Brand Names: None yet (currently an investigational drug)
• Drug Class: Monoclonal Antibody (Anti-angiogenic agent)
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Carotuximab is currently an investigational drug. It is not yet FDA-approved for standard use but has received “Fast Track” designation for certain cancers and is actively being tested in clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

As a Targeted Therapy and Immunotherapy, carotuximab works by stopping tumors from growing their own blood supply. Tumors need oxygen and nutrients to survive. To get them, tumors send out signals to build new blood vessels in a process called “angiogenesis.”

At the molecular level, carotuximab is a lab-made antibody designed to find and attach to a specific protein called CD105 (endoglin). CD105 is found in high amounts on the surface of the fast-growing blood vessel cells that surround a tumor.

Here is exactly how it works:

1. Blocking the Signal: CD105 normally acts like an antenna, picking up growth signals (specifically through the TGF-beta and Smad signaling pathways). Carotuximab covers this antenna.
2. Starving the Tumor: By blocking the Smad signaling pathway, the blood vessels cannot grow or organize. Without new blood vessels, the tumor starves and stops growing.
3. Immune Attack: Because it is an Immunotherapy, carotuximab also “flags” the tumor’s blood vessels. This flag tells the body’s natural immune system to come and destroy those specific blood vessel cells.

FDA Approved Clinical Indications

Currently, carotuximab is an investigational drug and is only available through clinical trials or special expanded access programs.

Oncological uses:

• There are no FDA-approved oncological uses yet. However, it is being actively tested for:
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Soft tissue cancers like Angiosarcoma

Non-oncological uses:

• There are currently no FDA-approved non-oncological uses. (It is being researched in eye diseases like macular degeneration under a different name, DE-122).

Dosage and Administration Protocols

Because carotuximab is still in clinical trials, the exact dosage depends on the specific study the patient is enrolled in. It is administered directly into a vein at a hospital or clinic.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because carotuximab is an antibody (a large protein), it is broken down by the body’s cellular protein-clearing system rather than being filtered out by the kidneys or liver. Specific dose adjustments for mild kidney (renal) or liver (hepatic) insufficiency are generally not required, though doctors will monitor organ health closely during the trial.

Clinical Efficacy and Research Results

Recent clinical data from 2020 to 2025 has shown very promising results, especially when carotuximab is combined with other cancer drugs.

• Advanced Prostate Cancer (2025 Data): In an ongoing Phase 2 clinical trial, patients with advanced, treatment-resistant prostate cancer received carotuximab alongside a hormone therapy pill (apalutamide). Interim results showed a median progression-free survival (PFS) of over 13 months. This was a major success, as it exceeded the trial’s goal of a 45% improvement. Additionally, 7 out of 9 evaluated patients saw a drop in their prostate-specific antigen (PSA) levels.
• Lung Cancer (2025 Data): Recent studies showed that carotuximab helps overcome drug resistance in Non-Small Cell Lung Cancer (NSCLC). By blocking CD105, carotuximab “wakes up” dormant cancer cells, making them sensitive again to standard targeted therapies like osimertinib.
• Safety Milestones: In July 2025, a safety review of the prostate cancer trial confirmed that the drug was well-tolerated, with zero severe (Grade 3 or 4) toxicities reported in the test group.

Safety Profile and Side Effects

While carotuximab targets cancer blood vessels safely in most patients, it can cause side effects.

Black Box Warning

• None currently: As an investigational medication, carotuximab does not yet carry an official FDA “Black Box Warning.” However, drugs in the anti-angiogenic class typically carry strong warnings regarding the risk of severe bleeding (hemorrhage) and problems with wound healing.

Common Side Effects (>10%)

• Nosebleeds (Epistaxis): The most common side effect due to the drug acting on blood vessels.
• Headache and Fatigue: Feeling unusually tired or having mild to moderate head pain.
• Infusion Reactions: Chills, fever, or mild rash during or shortly after the IV drip.

Serious Adverse Events

• Severe Bleeding: Because the drug stops blood vessel growth, there is a risk of serious internal bleeding.
• Poor Wound Healing: Cuts or surgical wounds may take much longer to heal.
• High Blood Pressure: Changes to the blood vessels can cause a spike in blood pressure.

Management Strategies:

• For Infusion Reactions: Doctors will give you premedications (like antihistamines or mild steroids) before the IV starts to prevent allergic reactions.
• For Bleeding: If severe bleeding occurs, the drug will be paused immediately. Doctors closely monitor your blood tests to make sure your blood can clot properly.

Connection to Stem Cell and Regenerative Medicine

Recent 2025 research has uncovered a fascinating connection between carotuximab and cancer stem-like cells (often called “persister cells”). In lung cancer, some cancer cells go into a dormant, sleep-like state to hide from chemotherapy. These persister cells act very much like stem cells, allowing the cancer to survive and regenerate later. Researchers discovered that these stem-like cancer cells have high amounts of CD105. By using carotuximab to target CD105, doctors can disrupt the cancer’s “dormancy,” forcing the stem-like cells to wake up so that other Immunotherapy and targeted drugs can successfully destroy them.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Coagulation Panel (PT/INR): To ensure your blood can clot normally before starting treatment.
• Complete Blood Count (CBC): To check your starting red and white blood cell levels.
• Baseline Blood Pressure: To monitor for any spikes during treatment.

Precautions During Treatment

• Watch for Bleeding: Be very careful when brushing your teeth or shaving, as you may bleed more easily.
• Surgery Planning: If you need any surgery or dental work, you must tell your surgeon you are on this medication, as it affects wound healing.

“Do’s and Don’ts”

• DO report any unusual headaches, dizziness, or bleeding (including dark stools or coughing up blood) to your trial doctor immediately.
• DO use a soft-bristled toothbrush and an electric razor to avoid cuts.
• DON’T take aspirin, ibuprofen, or blood-thinning supplements (like fish oil or Vitamin E) without your doctor’s strict permission.
• DON’T miss any scheduled clinical trial check-ups, as your team needs to monitor your progress closely.

Legal Disclaimer

This guide is for informational and educational purposes only and does not constitute medical advice. Carotuximab is currently an investigational medication and is not yet approved by the FDA for standard commercial use. It is only available to patients enrolled in approved clinical trials. Always consult with your oncologist or qualified healthcare provider regarding your specific diagnosis, treatment options, and eligibility for clinical trials. Never delay or disregard professional medical advice based on information provided in this guide.